Bioavailability and Solubility of Different Calcium-Salts As a Basis for Calcium Enrichment of Beverages
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
WO 2013/096420 Al 27 June 2013 (27.06.2013) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/096420 Al 27 June 2013 (27.06.2013) P O P C T (51) International Patent Classification: (72) Inventors; and A23L 1/236 (2006.01) (71) Applicants (for US only): PRAKASH, Indra [US/US]; 9750 Talisman Drive, Alpharetta, GA 30022 (US). (21) International Application Number: MARKOSYAN, Avetik [AM/MY]; A-5-8 Park Resid PCT/US2012/070562 ence, an 112h, Kuala Lumpur, 59200 (MY). (22) International Filing Date: CHATURVEDULLA, Venkata, Sai Prakash [IN/US]; 19 December 2012 (I 12.2012) 13300 Morris Road, Unit 107, Alpharetta, GA 30004 (US). CAMPBELL, Mary [US/US]; 5 171 Proctor Landing, Ac- (25) Filing Language: English worth, GA 30101 (US). SAN MIGUEL, Rafael [US/US]; (26) Publication Language: English 3277 Craggy Point, Se, Atlanta, GA 30339 (US). PURKAYASTHA, Siddhartha [US/US]; 615 Glenwood (30) Priority Data: Lane, Lombard, IL 60148 (US). JOHNSON, Marquita 61/577,202 19 December 201 1 (19. 12.201 1) US [US/US]; 10133 South Karlov Ave., Oak Lawn, IL 60453 61/65 1,099 24 May 2012 (24.05.2012) US (US). (71) Applicants (for all designated States except US): THE (74) Agents: KAUFMAN, Rebecca et al; King & Spalding, COCA-COLA COMPANY [US/US]; One Coca-Cola 1180 Peachtree Street, Atlanta, GA 30309 (US). Plaza, NW, Atlanta, GA 303 13 (US). PURECIRCLE SDN BHD [MY/MY]; PT 23419, Lengkuk Teknologi, (81) Designated States (unless otherwise indicated, for every Techpark @ ENSTEK, 71760 Bandar ENSTEK, Negeri kind of national protection available): AE, AG, AL, AM, Sembilan (MY). -
The Health Benefits of Calcium Citrate Malate: a Review of the Supporting Science
CHAPTER 6 The Health Benefits of Calcium Citrate Malate: A Review of the Supporting Science Susan Reinwald,* Connie M. Weaver,* and Jeffrey J. Kester† Contents I. Why Focus on Calcium Citrate Malate? 221 II. Ca Needs and Current Intakes 222 A. The role of Ca in the body 222 B. General Ca requirements 223 C. Specific Ca needs 224 D. Current intakes 226 E. Implications 231 III. Description and Properties of CCM 232 A. Chemical formula of CCM and its component anions 232 B. Ca content 232 C. How CCM is made 234 D. Aqueous solubility 235 E. CCM in fortified foods and beverages 237 F. CCM in dietary supplements 242 IV. Studies of Ca Bioavailability from CCM 244 A. Ca absorption 244 B. Factors that influence Ca absorption 256 C. How CCM fits with the influencing factors — human studies with CCM 257 D. Animal studies with CCM 269 *Department of Foods and Nutrition, Purdue University, West Lafayette, Indiana 47907 {Coffee & Snacks Technology Division, The Procter & Gamble Company, Miami Valley Innovation Center, Cincinnati, Ohio 45252 Advances in Food and Nutrition Research, Volume 54 # 2008 Elsevier Inc. ISSN 1043-4526, DOI: 10.1016/S1043-4526(07)00006-X All rights reserved. 219 220 Susan Reinwald et al. V. Studies of Ca Retention and Bone Building in Children and Adolescents 276 A. Ca balance studies 278 B. Bone density studies (2–3 years) 280 C. Long-term bone density studies (4–7 years) 283 VI. Studies of Bone Maintenance in Adults 289 A. Studies in postmenopausal women 290 B. Studies in elderly men and women — including effects on fracture risk and risk of falls 294 VII. -
Magnesium Malate, Used As a Novel Food Ingredient and As A
SCIENTIFIC OPINION ADOPTED: 15 May 2018 doi: 10.2903/j.efsa.2018.5292 Evaluation of di-magnesium malate, used as a novel food ingredient and as a source of magnesium in foods for the general population, food supplements, total diet replacement for weight control and food for special medical purposes EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Maged Younes, Peter Aggett, Fernando Aguilar, Riccardo Crebelli, Birgit Dusemund, Metka Filipic, Maria Jose Frutos, Pierre Galtier, Ursula Gundert-Remy, Gunter Georg Kuhnle, Claude Lambre, Jean-Charles Leblanc, Inger Therese Lillegaard, Peter Moldeus, Alicja Mortensen, Agneta Oskarsson, Ivan Stankovic, Ine Waalkens-Berendsen, Rudolf Antonius Woutersen, Matthew Wright, Harry McArdle, Paul Tobback, Fabiola Pizzo, Ana Rincon, Camilla Smeraldi and David Gott Abstract The present scientific opinion deals with the evaluation of the safety of di-magnesium malate (DMM) proposed as a novel food ingredient and as a source of magnesium for use in foods for the general population, food supplements, total diet replacement for weight control and food for special medical purposes (FSMP), and with the bioavailability of magnesium from this source. Additional information was sought from the applicant during the assessment process. However, despite several requests, the applicant did not provide the additional data. Consequently, the Panel performed this assessment on the basis of the available data and concluded that there was insufficient scientific evidence of a difference between the proposed novel food ingredient named as DMM and magnesium malate already authorised as a source of magnesium included in Annex II to Directive 2002/46/EC. Accordingly, the Panel was unable to assess the safety of DMM as a novel food ingredient. -
Attachment A2
Attachment A2 Draft variation to the Australia New Zealand Food Standards Code (Volume 2, Schedules S1 to S30) – Proposal P1025 Code Revision Australia New Zealand Food Standards Code Food Standards Australia New Zealand Act 1991 Volume 2, Schedules 1 to 30 Contents Schedule 1—RDIs and ESADDIs 7 S1.01 RDIs and ESADDIs for vitamins .......................................................... 7 S1.02 RDIs and ESADDIs for minerals ..........................................................8 S1.03 Calculation of retinol equivalents for carotene forms of vitamin A ........ 8 S1.04 Calculation of alpha-tocopherol equivalents for vitamin E .................... 9 Schedule 2—Units of measurement 10 S2.01 Units of measurement........................................................................ 10 Schedule 3—Identity and purity 12 S3.01 Substances with specifications in primary sources ............................ 12 S3.02 Substances with specifications in secondary sources ........................ 13 S3.03 Additional and supplementary requirements ...................................... 13 S3.04 Specifications for Advantame ............................................................ 14 S3.05 Specification for agarose ion exchange resin .................................... 14 S3.06 Specification for bentonite ................................................................. 15 S3.07 Specification for bromo-chloro-dimethylhydantoin ............................. 15 S3.08 Specification for carboxymethyl cellulose ion exchange resin ............ 16 -
Australia New Zealand Food Standards Code This Version
Australia New Zealand Food Standards Code Food Standards Australia New Zealand Act 1991 This Code consists of standards made under the Food Standards Australia New Zealand Act 1991. As in effect on [date of commencement] DRAFT This version contains amendments up to Amendment No. 148. Contents Australia New Zealand Food Standards Code 231 Schedule 1 RDIs and ESADDIsError! Reference source not found.Section S1—1 Name Schedules of the Code Schedule 1 RDIs and ESADDIs Note 1 This instrument is a standard under the Food Standards Australia New Zealand Act 1991 (Cth). The standards together make up the Australia New Zealand Food Standards Code. See also section 1.1.1—3. Standard 1.1.1 relates to introductory matters and standards that apply to all foods. This Standard specifies RDIs and ESADDIs for section 1.1.2—10. Note 2 The provisions of the Code that apply in New Zealand are incorporated by reference into a food standard under the Food Act 1981 (NZ). See also section 1.1.1—3. S1—1 Name This Standard is Australia New Zealand Food Standards Code — Schedule 1 — RDIs and ESADDIs. Note Commencement: This Standard commences on [date of commencement], being the date specified as the commencement date in notices in the Gazette and the New Zealand Gazette under section 92 of the Food Standards Australia New Zealand Act 1991 (Cth). See also section 93 of that Act. Australia New Zealand Food Standards Code 232 Schedule 1 RDIs and ESADDIsError! Reference source not found.Section S1—2 RDIs and ESADDIs for vitamins S1—2 RDIs and ESADDIs for vitamins -
Calcium Citrate Malate Composition
~" ' MM II II II MM II II III I Ml II I II J European Patent Office _ _ _ -•#»>■ © Publication number: 0 533 724 B1 Office_„. europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 26.04.95 © Int. CI.6: C07C 59/265, A61 K 31/1 9, C07C 59/245, C07C 51/41 © Application number: 91910588.2 @ Date of filing: 30.05.91 © International application number: PCT/US91/03779 © International publication number: WO 91/19692 (26.12.91 91/29) Q») CALCIUM CITRATE MALATE COMPOSITION. © Priority: 14.06.90 US 537313 © Proprietor: THE PROCTER & GAMBLE COM- 31.10.90 US 608055 PANY One Procter & Gamble Plaza @ Date of publication of application: Cincinnati 31.03.93 Bulletin 93/13 Ohio 45202 (US) © Publication of the grant of the patent: @ Inventor: FOX, Mary, Mora 26.04.95 Bulletin 95/17 13 Applewood Dr. Fairfield, OH 45014 (US) © Designated Contracting States: Inventor: HECKERT, David, Clinton AT BE DE FR GB IT NL 3561 Kehr Road Oxford, OH 45056 (US) © References cited: Inventor: LUHRSEN, Kenneth, Ray EP-A- 0 297 679 Route 1, Box 11 EP-A- 0 304 987 Aurora, IN 47001 (US) © Representative: Canonlcl, Jean-Jacques et al Procter & Gamble European Technical Cen- ter N.V. 00 Temselaan 100 ^ B-1853 Strombeek-Bever (BE) CM 00 00 w Note: Within nine months from the publication of the mention of the grant of the European patent, any person ® may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition CL shall be filed in a written reasoned statement.